1. Triptolide-Containing Formulation in Patients With Autosomal Dominant Polycystic Kidney Disease and Proteinuria: An Uncontrolled Trial 
Dongping Chen, MD, Yiyi Ma, MD, Xueqi Wang, PhD, Shengqiang Yu, MD, PhD, Lin Li, MD, Bing Dai, MD, Zhiguo Mao, MD, Hongchao Liu, MD, Shiyuan Liu, MD, Changlin Mei, MD 
American Journal of Kidney Diseases 
Volume 63, Issue 6, Pages (June 2014)
DOI: /j.ajkd
Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions

2. Figure 1
Change in 24-hour urine protein excretion, TKV, and eGFR in each of the 9 proteinuric ADPKD patients. The gray band shows 6-month Tripterygium treatment (Φ, treatment started; #, stopped) received by all. In addition, 2 male patients restarted Tripterygium treatment at 12 months. Patient 2 received an additional 6 months of treatment, halted treatment for 6 months, restarted the treatment, and continued to be followed up for another 12 months. Patient 7 received 18 months' additional treatment and continued to be followed up thereafter.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions